A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

• Conditions: Chronic Obstructive Pulmonary Disease
• Interventions: Drug: Lebrikizumab; Drug: Placebo

• Registration Number: NCT02546700
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

Phase II, randomized, double-blind, placebo-controlled, parallel-group clinical trial of lebrikizumab in participants with COPD and a history of exacerbations who are treated with inhaled corticosteroid (ICS) and at least one long-acting bronchodilator inhaler medication. This study will be conducted to assess the safety, efficacy, and patient-reported outcome (PRO) measures.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-09-09
• Study First Submitted QC: 2015-09-09
• Study First Posted: 2015-09-11
• Study Start: 2015-09-30
• Primary Completion: 2016-11-25
• Study Completion: 2016-11-25
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-05
• Last Update Posted: 2017-09-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 309

Inclusion Criteria

• Documented history of COPD greater than or equal to (>/=) 12 months prior to Visit 1
• Post-bronchodilator FEV1/FVC less than (<) 0.70 at Visit 1 or 2
• Post bronchodilator FEV1 <80% predicted at Visit 1 or 2
• Documented history of one or more acute COPD exacerbations requiring treatment with systemic corticosteroids and/or antibiotics or hospitalization within 12 months prior to Visit 1
• Current tobacco smoker or former smoker (having stopped smoking for at least 6 months prior to Visit 1) with a history of smoking >/=10 pack-years (20 cigarettes/day for 10 years)
• On inhaled corticosteroids (ICS) therapy for >/=6 months prior to Visit 1
• On an eligible bronchodilator medication for >/=6 months prior to Visit 1
• Chest X-ray or computed tomography (CT) scan within 6 months prior to Visit 1 or chest X-ray prior to Visit 2 that confirms absence of clinically significant lung disease besides COPD
• Demonstrated adherence with background COPD inhaler medication during screening period
• For female participants of childbearing age, use of single or combined contraceptive methods for the duration of the study

Exclusion Criteria

• History of severe allergic reaction or anaphylactic reaction to biologic agent or known hypersensitivity to lebrikizumab injection
• History of clinically significant pulmonary disease other than COPD
• Diagnosis of alpha-1-antitrypsin deficiency
• Lung volume reduction surgery or procedure within 12 months prior to Visit 1
• Supplemental oxygen requirement >2 liters/minute (L/min) at rest or with exertion
• Current diagnosis of asthma
• Participants participating in, or scheduled for, an intensive COPD rehabilitation program
• Maintenance oral corticosteroid therapy
• Treatment with systemic corticosteroids within 4 weeks prior to Visit 1 or during screen period
• Unstable ischemic heart disease or other relevant cardiovascular disorders
• Use of an immunomodulatory or immunosuppressive therapy including monoclonal antibodies (includes anti-interleukin-13 (IL) or anti-IL-4/IL-13 therapy)
• Body weight <40 kg
• Any infection that resulted in hospital admission for >/= 24 hours and/or treatment with oral, intravenous (IV), or intramuscular (IM) antibiotics within 4 weeks prior to Visit 1 or during screening
• Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening
• Active parasitic or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
• Received a live attenuated vaccine within 4 weeks prior to Visit 1 or during screening
• Active tuberculosis requiring treatment within 12 months prior to Visit 1
• Human immunodeficiency virus (HIV) or other known immunodeficiency
• Hepatitis or known liver cirrhosis
• Aspartate Aminotransferase (AST), Alanine Aminotransferase (ATL), or total bilirubin elevation >/=2.0 x upper limit of normal (ULN) during screening
• Clinically significant abnormality on screening electrocardiogram (ECG) or laboratory tests
• History of alcohol or drug abuse
• Pregnant or lactating

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Lebrikizumab: Biomarker-high	Lebrikizumab	Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
Lebrikizumab: Biomarker-low	Lebrikizumab	Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
Placebo: Biomarker-high	Placebo	Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
Placebo: Biomarker-low	Placebo	Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.

Primary Outcome Measures

Name	Time	Method
Absolute Change From Baseline in Pre-bronchodilator Forced Expiratory Volume (FEV1) at Week 12	Baseline, Week 12

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants with Adverse Events And Serious Adverse Events	Baseline up to Week 36
Minimum Observed Serum Trough Lebrikizumab Concentration (Cmin)	Pre-dose (Hour 0) at Weeks 4 and 12, at Week 24
Plasma Decay Half-Life (t1/2)	Pre-dose (Hour 0) on Day 1 (Baseline) and Weeks 1, 4, 8, 12, 16, 20; at Weeks 24, 28, and 36
Rate of Moderate or Severe COPD Exacerbation	Baseline up to Week 24
Absolute Change From Baseline in Post-bronchodilator FEV1 at Week 24	Baseline, Week 24
Time to First COPD Exacerbation	Baseline up to Week 24
Absolute Change From Baseline in Pre-bronchodilator FEV1 at Week 24	Baseline, Week 24
Change From Baseline in COPD Symptoms as Measured by the Overall Score of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) at Week 24	Baseline, Week 24
Change From Baseline in Cough and Sputum as Measured by the Cough and Sputum Domain Score of the EXACT at Week 24	Baseline, Week 24
Change From Baseline in Dyspnea as Assessed by the Baseline Dyspnea Index/Transition Dyspnea Index (BDI/TDI) at Week 24	Baseline, Week 24
Change From Baseline in Health-related Quality of Life as Assessed by the Overall Score of the Saint George's Respiratory Questionnaire for COPD (SGRQ-C) at Week 24	Baseline, Week 24
Percentage of Participants with Anti-therapeutic Antibody (ATA) to Lebrikizumab	Baseline up to Week 36

Trial Locations

Locations (65)

Achieve Clinical Research, LLC; 🇺🇸 Birmingham, Alabama, United States

Phoenix Medical Research Institute, LLC; Phoenix Medical Research Institute, LLC; 🇺🇸 Peoria, Arizona, United States

California Medical Research Associates, Inc.; 🇺🇸 Northridge, California, United States

Palmtree Clinical research Inc; 🇺🇸 Palm Springs, California, United States

Finlay Medical Research; 🇺🇸 Miami, Florida, United States

Progressive Medical Research; 🇺🇸 Port Orange, Florida, United States

Columbus Regional Research Institute; 🇺🇸 Columbus, Georgia, United States

Southeast Regional Res Group; 🇺🇸 Savannah, Georgia, United States

Centex Studies; 🇺🇸 Houston, Texas, United States

The Clinical Research Ctr; 🇺🇸 Saint Louis, Missouri, United States

Scroll for more (55 remaining)